BioSpace News Archive

BVI broadens its widely popular range of Malosa® single-use ophthalmic instruments to span cataract, oculoplastic, corneal refractive procedures and other office-based procedures

BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live.

Davis is the voice behind Mayo Clinic’s latest creative campaign “You Know Where to Go”

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that company management will participate in three upcoming virtual investor conferences in September: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Monday, September 14, 2020 Presentation: 11:00 a.m. ET Cantor Virtual Global Healthcare Confer

Teva to Present New Data on AUSTEDO ® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, today announced its Chief Financial Officer (CFO) Stephen Randall will retire after more than 10 years with Titan. As part of the Company’s succession planning process, Monique L. Delorme, currently Vice President, Finance at Titan, will be promote

Ensysce Biosciences Inc., a clinical stage company launching new solutions for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, today announced the appointment of Steven R. Martin to its Board of Directors. Mr. Martin is Senior VP and Chief Financial Officer of Armata Pharmaceuticals, Inc. (NYSE: ARMP

Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually. A live, audio webcast for this event will be available on the Investor Relations sectio

Funds to pursue development of INV-101 and other promising peripheral CB1 blockers to clinical proof-of-concept, as well as to expand the Company’s operations Board of Inversago strengthened with the appointment of three new directors MONTREAL--( BUSINESS WIRE )-- Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (CDN$47 million) Series B financing round le

Solution Combines Nihon Kohden’s Proprietary Prefense® Early Detection & Notification System with Wireless Wearable Monitors to Expand Monitoring Capacity